FDA grants fast track status to Rznomics’ RZ-001 for HCC
The US FDA has granted fast track designation to Rznomics' RZ-001 for the treatment of hepatocellular carcinoma (HCC).
The US FDA has granted fast track designation to Rznomics' RZ-001 for the treatment of hepatocellular carcinoma (HCC).
What's Your Reaction?
